Naproxen
A Reappraisal of its Pharmacology, and Therapeutic Use in Rheumatic Diseases and Pain States

Peter A. Todd and Stephen P. Clissold
Adis Drug Information Services, Auckland, New Zealand

Various sections of the manuscript reviewed by: P.M. Brooks, Department of Rheumatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; J.C. Chang, Department of Medicine, Wright State University School of Medicine, Dayton, Ohio, USA; P. Davis, Department of Rheumatology/Clinical Immunology, University of Alberta, Edmonton, Alberta, Canada; M.A. Goldberg, Passaic Internal Medicine Group, Passaic, New Jersey, USA; F.D. Hart, Harley Street, London, England; G. Husby, Department of Rheumatology, University of Tromso Institute of Clinical Medicine, Tromso, Norway; T. Ishizaki, Clinical Research Institute, National Medical Center, Tokyo, Japan; I. Milson, Department of Obstetrics & Gynaecology, East Hospital, Goteborg, Sweden; M. Orme, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England; S.H. Roth, Arthritis Center Ltd, Phoenix, Arizona, USA; J.D. Sargent, Headache and Internal Medicine Research Center, The Menninger Clinic, Topeka, Kansas, USA; K. Tsurumi, Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan; J.A. Vale, West Midlands Poisons Unit, Dudley Road Hospital, Birmingham, England; F.A. van den Ouweland, Department of Epidemiology, Erasmus University Rotterdam, Rotterdam, The Netherlands; G. Vetter, Klinik Auerbach, Auerbach, West Germany.

Summary ................................................................. 92

1. Pharmacodynamic Properties ................................................................. 96
   1.1 Anti-Inflammatory, Analgesic and Antipyretic Effects ........................................ 96
      1.1.1 Anti-Inflammatory Effects .............................................................................. 96
      1.1.2 Analgesic Effects ....................................................................................... 96
      1.1.3 Antipyretic Effects .................................................................................... 96
   1.2 Gastrointestinal Effects ............................................................................. 96
   1.3 Effects on Arachidonic Acid Metabolism ................................................... 99
   1.4 Effects on Platelet Aggregation and Bleeding Time ...................................... 99
   1.5 Effects on Renal Function ......................................................................... 99
   1.6 Effects on Hepatic Function ..................................................................... 101
   1.7 Effects on Collagen Metabolism ............................................................... 101
   1.8 Effects on Leucocyte Function .................................................................. 101
   1.9 Effects on Endometrial Function ............................................................. 101
   1.10 Effects on Ocular Function .................................................................... 102
   1.11 Effects in Cardiovascular Disease ......................................................... 102

2. Pharmacokinetic Properties ................................................................. 103
   2.1 Absorption and Plasma Concentrations .................................................. 103
   2.2 Distribution ............................................................................................ 104
   2.3 Metabolism and Excretion .................................................................. 104
Synopsis

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain nonrheumatic conditions. It may be administered orally or rectally using a convenient once or twice daily regimen. Dosage adjustments are not usually required in the elderly or those with mild renal or hepatic impairment although it is probably prudent to start treatment at a low dosage and titrate upwards in such groups of patients.

Numerous clinical trials have confirmed that the analgesic and anti-inflammatory efficacy of naproxen is equivalent to that of the many newer and established NSAIDs with which it has been compared. The drug is effective in many rheumatic diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and nonarticular rheumatism, in acute traumatic injury, and in the treatment of and prophylaxis against acute pain.